U.S. Markets closed

Trade Alert: The Of Immunomedics, Inc. (NASDAQ:IMMU), Bryan Ball, Has Just Spent US$71k Buying Shares

Simply Wall St

Whilst it may not be a huge deal, we thought it was good to see that Bryan Ball, who is a company insider, recently bought US$71k worth of stock, for US$14.18 per share. Even though that isn't a massive buy, it did increase their holding by 100%, which is a arguably a good sign.

View our latest analysis for Immunomedics

Immunomedics Insider Transactions Over The Last Year

Notably, that recent purchase by Bryan Ball is the biggest insider purchase of Immunomedics shares that we've seen in the last year. So it's clear an insider wanted to buy, at around the current price, which is US$14.37. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. In this case we're pleased to report that the insider bought shares at close to current prices. Bryan Ball was the only individual insider to buy shares in the last twelve months.

Bryan Ball bought a total of 10000 shares over the year at an average price of US$13.76. The chart below shows insider transactions (by individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

NasdaqGM:IMMU Recent Insider Trading, October 5th 2019

Immunomedics is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Insider Ownership

Many investors like to check how much of a company is owned by insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. From what we can see in our data, insiders own only about US$238k worth of Immunomedics shares. It's always possible we are missing something but from our data, it looks like insider ownership is minimal.

So What Does This Data Suggest About Immunomedics Insiders?

The recent insider purchase is heartening. And an analysis of the transactions over the last year also gives us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that Immunomedics insiders are expecting a bright future. Of course, the future is what matters most. So if you are interested in Immunomedics, you should check out this free report on analyst forecasts for the company.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.